Quantcast

Latest Belimumab Stories

2014-05-19 08:28:15

HERZLIYA, Israel, May 19, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of consultants Lee S. Simon, MD, FACP, FACR and David Isenberg, MD, for the planned Phase II trial for the Company's hCDR1 compound for the treatment of...

2014-04-28 12:27:09

Rheumatologists Cite Improved Health-Related Quality of Life, Improved Effect in Disease Activity among Unmet Needs, According to Findings from Decision Resources Group BURLINGTON, Mass., April 28, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and EU5 rheumatologists agree that new therapies for the treatment of moderate to severe systemic lupus erythematosus (SLE) that offer improved effect on disease activity and renal organ domain scores over current therapies...

2014-03-25 08:29:48

HERZLIYA, Israel, March 25, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of Daniel J. Wallace, MD and Murray Urowitz, MD, two experts in rheumatology, as consultants for the planned Phase II trial for the Company's hCDR1...

2014-03-11 23:33:04

Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus erythematosus (SLE). Birmingham, Alabama (PRWEB) March 11, 2014 *To see if you qualify for this Lupus Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no...

2014-01-08 08:28:37

HERZLIYA, Israel, January 8, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced it has signed a licensing agreement with Yeda Research and Development Company Ltd. ("Yeda") to develop hCDR1, a Phase II-ready asset for the treatment of...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.